Spago Nanomedical AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPAGO.ST research report →
Companyspagonanomedical.se
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
- CEO
- Mats Hansen
- IPO
- 2013
- Employees
- 13
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $48.22M
- P/E
- -3.32
- P/S
- 398.51
- P/B
- 3.55
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -17772.73%
- Op Margin
- -25890.08%
- Net Margin
- -21419.01%
- ROE
- -120.70%
- ROIC
- -125.10%
Growth & Income
- Revenue
- $437.00K · -77.13%
- Net Income
- $-26,554,000 · 18.32%
- EPS
- $-0.07 · 35.64%
- Op Income
- $-30,864,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.46
- 52W Low
- $0.08
- 50D MA
- $0.12
- 200D MA
- $0.15
- Beta
- 1.30
- Avg Volume
- 351.73K
Get TickerSpark's AI analysis on SPAGO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPAGO.ST Coverage
We haven't published any research on SPAGO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPAGO.ST Report →